Eli Lilly reported that in addition to achieving greater reductions in weight, Zepbound-treated patients achieved greater reductions in waist circumference compared to those treated with Novo Nordisk’s Wegovy. Full details from the head-to-head Phase 3 test were presented at the European Congress on Obesity meeting.
The post Details From Head-to-Head Phase 3 Test Give Fuller Picture of Zepbound’s Edge Over Wegovy appeared first on MedCity News.
